We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
신규 편입 · 포트폴리오 비중 0.13%
신규 편입 · 포트폴리오 비중 0.03%
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $55.39 · 15 analysts
Stored first · Google News · Yahoo Finance (English)
LEGN Reinstated by JP Morgan -- Rating Set to Neutral - GuruFocus
LEGN Reinstated by JP Morgan -- Rating Set to Neutral GuruFocus
JPMorgan Initiates Coverage of Legend Biotech (LEGN) with Neutra - GuruFocus
JPMorgan Initiates Coverage of Legend Biotech (LEGN) with Neutra GuruFocus
Legend Biotech Corporation (LEGN) Stock Analysis: A Promising 111% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Legend Biotech Corporation (LEGN) Stock Analysis: A Promising 111% Potential Upside in the Biotech Sector DirectorsTalk Interviews
JPMorgan resumes Legend Biotech stock coverage with neutral rating - Investing.com
JPMorgan resumes Legend Biotech stock coverage with neutral rating Investing.com
Legend Biotech (LEGN) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Legend Biotech (LEGN) Short Interest & Short Float | Updated Jul 2026 MarketBeat
RBC Capital Adjusts Legend Biotech Price Target to $63 From $64, Maintains Outperform Rating
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 10. | After market close (AMC) | $0.28 | — | — | $365.15M | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 18. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 05. 14. | TD Cowen | — | Maintain | Hold → Hold | — | TD Cowen: Hold |
| 2026. 05. 14. | Morgan Stanley | — | Maintain | Overweight → Overweight | — | Morgan Stanley: Overweight |
| 2026. 05. 14. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
| 2026. 04. 21. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 04. 15. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
Price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 3,886,017 | $70.3M | 0.13% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 2,784,806 | $60.54M | 0.10% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 1,890,396 | $34.2M | 0.03% | — | New position |
| 4 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 526,070 | $11.44M | 0.02% | — | New position |